Is cemiplimab already on the market in the country?

Cemiplimab (Cemiplimab) is an immunotherapy drug that has received great attention globally, but as of now, it has not been officially approved for marketing in the Chinese market. As a new type of PD-1 monoclonal antibody drug, it was first developed by Regeneron and Sanofi in the United States, and was the first to be approved by the U.S. FDA in 2018 for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma. Since then, its indications have gradually expanded to cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), non-small cell lung cancer (NSCLC) and other tumor types, and a certain clinical application pattern has gradually formed in the European and American markets.

In the domestic market, because cimepilimab has not yet been approved by the State Food and Drug Administration, patients are currently unable to purchase the drug through formal channels. This also means that it is not included in the medical insurance catalog, and price information is not yet transparent in China. For patients in need of medicine, they can only learn about the overseas selling price through cross-border channels, and the overseas version of cimipilimab is more expensive, which also limits its domestic accessibility to a certain extent. In contrast, a number of PD-1 inhibitors have been launched in China and are included in medical insurance, such as sintilimab, camrelizumab, etc., which have more advantages in price and availability. Therefore, cimepilimab has not been widely used in domestic clinical practice for the time being.

It is worth noting that as the Chinese pharmaceutical market accelerates its integration with international standards, cimepilimab is more likely to be launched domestically in the future. Once it enters the Chinese market, it will not only further enrich the treatment options for clinicians, but may also form differentiated complements with domestically produced PD-1 drugs. Especially in certain indication areas that are not fully covered by domestic drugs, cimepilimab is expected to fill the clinical gaps.

To sum up, cimepilimab is currently not on the market for sale in China, nor is it included in the scope of medical insurance reimbursement, so the specific price information is unclear.

Reference materials:https://www.libtayohcp.com/